Since the early 2000s, the paradigm shift of pharmaceutical companies from producing essential antibiotics to more “fashionable” treatments such as those for cancer and chronic disease has been well noted.
Antibiotic resistance is still a huge problem throughout the world. Antibiotic resistance occurs when an antibiotic has lost its ability to effectively control or kill bacterial growth, so when using this antibiotic to treat an infection, the bacteria aren’t killed.
However, there is hope in the fact that a study performed by Public Health England, the number of MRSA bacteraemias has reduced from 4451 2007/8 to less than 800 in 2013/14. This significant drop has shown that MRSA management has improved (by quarantining patients more quickly and identifying MRSA more rapidly), but more still needs to be done.
The problem occurred when Neisseria Gonorrhoeae, the bacterium responsible for causing the disease, became resistant to Azithromycin, meaning that the only drug able to treat it was Ceftriaxone.
However, widespread use of the second line drug raised fears that the strain would also become resistant to that (as a result of increased exposure), leading to an untreatable illness. Gonorrhoea can in rare cases lead to infertility and septicaemia, meaning that control of the illness was paramount.